SCHEMBL3324952

SCHEMBL3324952

CCOc1ccc(C2C(C(=O)OC(C)C)=C(C)NC3=C2C(=O)CC(c2ccc(OC)cc2)C3)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.51
HPGD P15428 7/20 0.51
MAPK1 P28482 3/20 0.51
MAPT P10636 2/20 0.51
MEN1 O00255 1/20 0.51
ALOX15 P16050 1/20 0.51
KMT2A Q03164 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
KDM4E B2RXH2 13/20 0.51
GAA P10253 7/20 0.51
HSD17B10 Q99714 6/20 0.51
LMNA P02545 3/20 0.51
USP2 O75604 3/20 0.50
TSHR P16473 2/20 0.50
RAB9A P51151 1/20 0.50
POLB P06746 3/20 0.47
AGTR1 P30556 1/20 0.47
CASP1 P29466 6/20 0.45
CASP7 P55210 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3323588 0.92 ALDH1A1 (0.54) ALDH1A1HPGDMAPK1MAPTMEN1
SCHEMBL3323171 0.90 ALDH1A1 (0.52) ALDH1A1HPGDMAPK1MAPTMEN1
SCHEMBL3326692 0.90 ALDH1A1 (0.47) ALDH1A1HPGDMAPK1MAPTMEN1
SCHEMBL3324953 0.88 ALDH1A1 (0.53) ALDH1A1HPGDMAPK1MAPTMEN1
SCHEMBL3323110 0.88 KDM4E (0.64) ALDH1A1HPGDMAPK1MAPTMEN1
SCHEMBL3330006 0.86 ALDH1A1 (0.53) ALDH1A1HPGDMAPK1MAPTMEN1
SCHEMBL3326475 0.84 ALDH1A1 (0.52) ALDH1A1HPGDMAPK1MAPTMEN1
SCHEMBL5312995 0.84 KDM4E (0.67) ALDH1A1HPGDMAPK1MAPTMEN1
SCHEMBL13333412 0.84 KDM4E (0.55) ALDH1A1HPGDMAPK1MAPTMEN1
SCHEMBL3323799 0.83 KDM4E (0.56) ALDH1A1HPGDMAPK1MEN1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 ALDH1A1 2615/4885HPGD 265/4885MAPK1 1851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.